Markets:

Overview

News

Currencies

International

Treasuries

Havn Life Sciences Inc (OP:HAVLF)

0.0001 UNCHANGED

Last Price Updated: 3:52 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Havn Life Sciences Inc

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗

July 31, 2024

Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.

Via Benzinga

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance ↗

August 19, 2022

Biotech psychedelics company HAVN Life Sciences Inc. (OTC: HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean (“ABO”), previously announced on July...

Via Benzinga

Learn About HAVN Life's New Shares Consolidation, What Changes And What Remains ↗

August 01, 2022

A key player in the biotech-meets-psychedelics space, HAVN Life Sciences Inc.

Via Benzinga

HAVN Life Sciences & Optimi Health Corp Announce Supply Agreements, Here Are The Details ↗

June 28, 2022

Two publicly traded psychedelics companies announced supply agreements. HAVN Life Sciences (OTC: HAVLF) will provide mental health clinic MPB Group Inc. with psilocybin-containing mushrooms for its...

Via Benzinga

Psyched: Cathie Wood Invests In Psychedelics Co ATAI, Bill Approved in Utah, AI Startup To 'Design States Of Mind' ↗

February 14, 2022

The psychedelics sector received its latest sign of acceptance from Wall Street with famed investor Cathie Wood taking a position ...

Via Benzinga

Amanita Muscaria: A Legal Psychoactive Mushroom With Potential Therapeutic Effects ↗

April 22, 2021

Amanita Muscaria is an understudied species of psychoactive mushroom that’s as commonplace as it is misunderstood. The iconic red-c...

Via Benzinga

HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market ↗

February 10, 2022

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function,...

Via Benzinga

Havn Life Buys Subscription-Based Functional Mushroom Co. With Significant US Consumer Base ↗

December 20, 2021

Biotech company Havn Life Sciences Inc. (CSE:HAVN) (OTC: HAVLF) is purchasing functional mushroom wellness brand Spore Life Sciences Inc. The Deal Details Under the deal...

Via Benzinga

HAVN Life Successfully Exports Naturally Derived Psilocybin From Its Jamaica Facility Into Canada ↗

November 23, 2021

Demonstrating the integrity of its supply chain from Jamaica into Canada, biotechnology company HAVN Life Sciences (OTCPK: HAVLF) achieved a milestone with...

Via Benzinga

Former Tilray CEO Joins Psychedelics Company ↗

October 07, 2021

More big names in cannabis are switching to psychedelics. Greg Engel, former CEO of Tilray (NASDAQ:

Via Benzinga

Topics Cannabis

Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study ↗

September 27, 2021

The Week In Psychedelics:

Via Benzinga

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics ↗

September 13, 2021

Last Week In Psychedelics:

Via Benzinga

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold ↗

August 30, 2021

Contents

Via Benzinga

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected ↗

August 02, 2021

Last week in Psychedelics:

Via Benzinga

How To Invest In "Magic Mushrooms" (Psychedelics) ↗

July 09, 2021

A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.

Via Talk Markets

HAVN Life is Looking for a Safe Haven to Mental Health Through Psychedelic Medicine ↗

June 10, 2021

Most companies' success stories come as a result of wanting to accomplish a greater purpose. For HAVN Life Sciences Inc. (CSE: HAVN) (OTC PINK: HAVLF) (FSE: 5NP) CEO Tim Moore...

Via Benzinga

Psychedelic Drug Stocks Index -21% In May; Now -25% YTD ↗

May 31, 2021

46 psychedelic drug stocks now trade on the various North American stock exchanges and the 11 with the largest market capitalizations make up the Pure-Play Psychedelic Drug Stocks Index.

Via Talk Markets

Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public ↗

May 17, 2021

Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa...

Via Benzinga

Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M ↗

May 10, 2021

Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Havn Life Sciences Inc (OP:HAVLF)

Headline News about Havn Life Sciences Inc

Starting at $3.75/week.

Subscribe Today